Active Surveillance for Cancer of the Prostate (ASCaP)
The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.
About This Trial
- This study is evaluating an approach called active surveillance, which closely monitors early-stage prostate cancer instead of immediately starting treatments like surgery or radiation.
- It is designed for men with low-risk cancer that has not spread beyond the prostate and who have not received any prior prostate cancer treatments.
- Under this approach, doctors carefully track the cancer and only begin treatment if tests show it is starting to grow.
- Before joining, you should know that participating requires attending regular follow-up visits and agreeing to undergo repeated prostate tissue samples, or biopsies, to ensure the cancer remains safe to watch.
More Information
- Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression.
- A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.
Who Can Enroll
- Age Range: 30 - 85 years
- Gender: Male
- Who This Trial is For: This study is evaluating an approach called active surveillance, which closely monitors early-stage prostate cancer instead of immediately starting treatments like surgery or radiation.
Study Details
- Start Date: July 4, 2009
- Lead Sponsor: Jonsson Comprehensive Cancer Center
Full Eligibility Criteria
Inclusion Criteria
- Histologically confirmed adenocarcinoma of the prostate.
- Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.
- No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).
- Patient has elected Active Surveillance as preferred management plan for prostate cancer.
- Patient consent has been obtained according to local Institutional Review Board .
- Patient is accessible and compliant for follow-up.
Exclusion Criteria
- Unwillingness or inability to undergo serial prostate biopsy.
- Overall life expectancy less than 2 years
- Advanced prostate cancer
Treatments
- Other: Active surveillance